ADCs

How Lessons from Breast Cancer Are Shaping ADC Development Across Solid Tumors

David Alvaro, Ph.D.

Pharma's Almanac

Heme-Onc

Therapeutic and Diagnostic Advances Benefiting Patients with Hematologic Malignancies

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Heme-Onc

The Next Generation of Targeted Therapies in Hematologic Malignancies

Pathfinder

Site-Specific vs. Stochastic ADC Conjugation: Which Antibody–Drug Conjugate Strategy Is Better?

Nice Insight

Masked Antibody

Expanding the Oncology Therapeutic Window Through Masked Antibody Technology

Sean McCarthy, Ph.D; David Alvaro, Ph.D.

CytomX Therapeutics

Pathfinder

Cleavable vs. Non-Cleavable ADC Linkers: Which Antibody–Drug Conjugate Strategy Is Better?

Nice Insight

ATMP Supply Chain

Maintaining Resilient Supply Chains for Advanced Therapies

Pharma's Almanac

AOCs

Antibody–Oligonucleotide Conjugates Clinical Manufacturing — A New Paradigm Shift of Bio-Conjugates for Therapeutics

Muctarr Sesay, Ph.D.; Natalia Bourguignon, Ph.D.

GBI Biomanufacturing

Asia Manufacturing

APAC Expands Specialized Manufacturing Capabilities Across High-Value Modalities

Pharma's Almanac

ADC Formulation

Controlling Complexity in ADC Formulation Development

Eunbi Iris Cho, Ph.D.

Samsung Biologics

U.S. CDMO Capacity

More Than Capacity: What the Latest U.S. CDMO Expansion Wave Reveals About Specialized Manufacturing Demand

Pharma's Almanac

Roundtable

How is the increasing complexity of modalities reshaping CDMO differentiation and specialization strategies?

Pharma's Almanac

ADCs

Re-Engineering ADCs for Autoimmune and Inflammatory Disease

David Alvaro, Ph.D.

Pharma's Almanac

Conjugation

Why ADC Conjugation Strategy Is Now a CMC Decision

David Alvaro, Ph.D.

Pharma's Almanac

ADC Platform

From mAbs to ADCs: Rethinking the Platform Manufacturing Model

David Alvaro, Ph.D.

Pharma's Almanac

ADC Linkers

Linker Chemistry as the Hidden Determinant of ADC Success

David Alvaro, Ph.D.

Pharma's Almanac

ADC Engineering

Engineering Antibodies for Precision Payload Delivery

David Alvaro, Ph.D.

Pharma's Almanac

Conjugate Payloads

Beyond Cytotoxins: Expanding the Payload Landscape for Antibody-Based Conjugates

David Alvaro, Ph.D.

Pharma's Almanac

ADCs

Accelerating ADC Analytical Method Development Through Platform Innovation

Jaeook Kim, Ph.D.

Samsung Biologics

ADCs

Improved Efficacy and Safety Driving Resurging Interest in ADCs

Cynthia A. Challener, Ph.D.

Pharma's Almanac